Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type (302 views visite) (PDF public pubblico 99 views visite)
Cancers (ISSN: 2072-6694linking), 2019 Jan 24; 11(2): 139-139.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 6.126, 5-year impact factor Impact factor a 5 anni: 0
Url: Not available. Non disponibile.
Keywords Parole chiave: Cell Migration And Invasion, Epithelial-Mesenchymal Transition, Stemness, Triple-Negative Breast Cancer, Alphavbeta3 Integrin, Psirgdechi,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. billy.hill@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. achiara.sarnella@gmail.com., Dipartimento di Farmacia, Universita degli Studi di Napoli "Federico II", 80131 Naples, Italy. domenica.capasso@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. daniela.comegna@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. annarita.delgatto@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. matteo.gramanzini@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. sandra.albanese@ibb.cnr.it., Istituto di Cristallografia-CNR, 70126 Bari, Italy. msaviano@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. lzaccaro@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. antonella.zannetti@cnr.it.,
References Riferimenti:
Not available. Non disponibili.
Cancers (ISSN: 2072-6694linking), 2019 Jan 24; 11(2): 139-139.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 6.126, 5-year impact factor Impact factor a 5 anni: 0
Url: Not available. Non disponibile.
Keywords Parole chiave: Cell Migration And Invasion, Epithelial-Mesenchymal Transition, Stemness, Triple-Negative Breast Cancer, Alphavbeta3 Integrin, Psirgdechi,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. billy.hill@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. achiara.sarnella@gmail.com., Dipartimento di Farmacia, Universita degli Studi di Napoli "Federico II", 80131 Naples, Italy. domenica.capasso@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. daniela.comegna@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. annarita.delgatto@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. matteo.gramanzini@ibb.cnr.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. sandra.albanese@ibb.cnr.it., Istituto di Cristallografia-CNR, 70126 Bari, Italy. msaviano@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. lzaccaro@unina.it., Istituto di Biostrutture e Bioimmagini-CNR, 80145 Naples, Italy. antonella.zannetti@cnr.it.,
References Riferimenti:
Not available. Non disponibili.
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of alphavbeta(3) integrin has been well established as a driver of cancer progression, stemness, and metastasis. Here, we showed that the high levels of alphavbeta(3) are associated with MES-TNBC and therefore exploited the possibility to target this integrin to reduce the aggressiveness of this carcinoma. To this aim, MES-TNBC cells were treated with a novel peptide, named psiRGDechi, that we recently developed and characterized for its ability to selectively bind and inhibit alphavbeta(3) integrin. Notably, psiRGDechi was able to hamper adhesion, migration, and invasion of MES-TNBC cells, as well as the capability of these cells to form vascular-like structures and mammospheres. In addition, this peptide reversed EMT program inhibits mesenchymal markers. These findings show that targeting alphavbeta(3) integrin by psiRGDechi, it is possible to inhibit some of the malignant properties of MES-TNBC phenotype.
The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of alphavbeta(3) integrin has been well established as a driver of cancer progression, stemness, and metastasis. Here, we showed that the high levels of alphavbeta(3) are associated with MES-TNBC and therefore exploited the possibility to target this integrin to reduce the aggressiveness of this carcinoma. To this aim, MES-TNBC cells were treated with a novel peptide, named psiRGDechi, that we recently developed and characterized for its ability to selectively bind and inhibit alphavbeta(3) integrin. Notably, psiRGDechi was able to hamper adhesion, migration, and invasion of MES-TNBC cells, as well as the capability of these cells to form vascular-like structures and mammospheres. In addition, this peptide reversed EMT program inhibits mesenchymal markers. These findings show that targeting alphavbeta(3) integrin by psiRGDechi, it is possible to inhibit some of the malignant properties of MES-TNBC phenotype.
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
No results. Nessun risultato. |
Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type
Capozza M, Anemone A, Dhakan C, Della Peruta M, Bracesco M, Zullino S, Villano D, Terreno E, Longo DL, Aime S
* GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[(18)F]F-FDG-PET (0 visite)
Mol Imaging Biol (ISSN: 1536-1632linking), 2021 Aug 12; N/D: N/D-N/D.
Impact Factor:
Dettagli Esporta in BibTeX Esporta in EndNote
Agnello L, Tortorella S, D’argenio A, Carbone C, Camorani S, Locatelli E, Auletta L, Sorrentino D, Fedele M, Zannetti A, Franchini MC, Cerchia L
* Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors (5 visite)
J Exp Clin Canc Res (ISSN: 1756-9966electronic, 0392-9078linking), 2021 Jul 22; 40(1): 239-239.
Impact Factor: 11.161
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
* Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer (78 visite) (PDF 41 visite)
J Exp Clin Canc Res (ISSN: 0392-9078linking, 1756-9966, 1756-9966electronic), 2020 Sep 7; 39(1): 180-180.
Impact Factor: 7.068
Dettagli Esporta in BibTeX Esporta in EndNote
Russi S, Verma HK, Laurino S, Mazzone P, Storto G, Nardelli A, Zoppoli P, Calice G, La Rocca F, Sgambato A, Lucci V, Falco G, Ruggieri V
* Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells (169 visite)
Int J Mol Sc (ISSN: 1422-0067linking, 1661-6596, 1422-0067electronic), 2019 Jul 31; 20(15): N/D-N/D.
Impact Factor: 4.183
Dettagli Esporta in BibTeX Esporta in EndNote
Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G
* Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 alpha/beta pathways (190 visite)
Mol Carcinog (ISSN: 0899-1987linking), 2019 Mar 4; 58(7): 1181-1193.
Impact Factor: 3.851
Dettagli Esporta in BibTeX Esporta in EndNote
Bolzati C, Salvarese N, Carpanese D, Seraglia R, Melendez-alafort L, Rosato A, Capasso D, Saviano M, Del Gatto A, Comegna D, Zaccaro L
* [(99m)Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of alphavbeta3 Integrin: Synthesis, Structure-Activity and Pharmacokinetic Studies (354 visite)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print, 1520-4804electronic), 2018 Nov 8; 61(21): 9596-9610.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill B, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L
* Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer (595 visite) (PDF 130 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic, 1838-7640linking), 2018 Oct 6; 8(18): 5178-5199.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Comegna D, Zannetti A, Del Gatto A, De Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L
* Chemical Modification for Proteolytic Stabilization of the Selective alphavbeta3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells (897 visite) (PDF 195 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 Dec 14; 60(23): 9874-9884.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Depalo N, Corricelli M, De Paola I, Valente G, Iacobazzi RM, Altamura E, Debellis D, Comegna D, Fanizza E, Denora N, Laquintana V, Mavelli F, Striccoli M, Saviano M, Agostiano A, Del Gatto A, Zaccaro L, Curri ML
* NIR Emitting Nanoprobes Based on Cyclic RGD Motif Conjugated PbS Quantum Dots for Integrin-Targeted Optical Bioimaging (383 visite) (PDF 176 visite)
Acs Appl Mater Inter (ISSN: 1944-8244), 2017 Dec 13; 9(49): 43113-43126.
Impact Factor: 8.097
Dettagli Esporta in BibTeX Esporta in EndNote
Hill BS, Pelagalli A, Passaro N, Zannetti A
* Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype (284 visite)
Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2017 Sep 22; 8(42): 73296-73311.
Impact Factor: 5.168
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A
* Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRbeta Aptamer (640 visite) (PDF 202 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic), 2017 Aug 22; 7(14): 3595-3607.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L
* Aptamer-mediated impairment of EGFR-integrin alphavbeta3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (431 visite) (PDF 215 visite)
Sci Rep (ISSN: 2045-2322, 2045-2322electronic, 2045-2322linking), 2017 Apr 20; 7: 46659-46659.
Impact Factor: 4.122
Dettagli Esporta in BibTeX Esporta in EndNote
Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (887 visite) (PDF 273 visite)
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 7.36
Dettagli Esporta in BibTeX Esporta in EndNote
Romano S, Staibano S, Greco A, Brunetti A, Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B, Romano M
* FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential (404 visite) (PDF 232 visite)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2013 Apr 4; 4(6): e578-e578.
Impact Factor: 5.333
Dettagli Esporta in BibTeX Esporta in EndNote
Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (410 visite)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (432 visite)
J Transl Med (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
Dettagli Esporta in BibTeX Esporta in EndNote
16 Records (15 escludendo Abstract e Conferenze).
Impact factor totale: 90.442 (85.109 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 76.42 (71.087 escludendo Abstract e Conferenze).
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Capozza M, Anemone A, Dhakan C, Della Peruta M, Bracesco M, Zullino S, Villano D, Terreno E, Longo DL, Aime S
* GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[(18)F]F-FDG-PET (0 visite)
Mol Imaging Biol (ISSN: 1536-1632linking), 2021 Aug 12; N/D: N/D-N/D.
Impact Factor:
Dettagli Esporta in BibTeX Esporta in EndNote
Agnello L, Tortorella S, D’argenio A, Carbone C, Camorani S, Locatelli E, Auletta L, Sorrentino D, Fedele M, Zannetti A, Franchini MC, Cerchia L
* Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors (5 visite)
J Exp Clin Canc Res (ISSN: 1756-9966electronic, 0392-9078linking), 2021 Jul 22; 40(1): 239-239.
Impact Factor: 11.161
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
* Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer (78 visite) (PDF 41 visite)
J Exp Clin Canc Res (ISSN: 0392-9078linking, 1756-9966, 1756-9966electronic), 2020 Sep 7; 39(1): 180-180.
Impact Factor: 7.068
Dettagli Esporta in BibTeX Esporta in EndNote
Russi S, Verma HK, Laurino S, Mazzone P, Storto G, Nardelli A, Zoppoli P, Calice G, La Rocca F, Sgambato A, Lucci V, Falco G, Ruggieri V
* Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells (169 visite)
Int J Mol Sc (ISSN: 1422-0067linking, 1661-6596, 1422-0067electronic), 2019 Jul 31; 20(15): N/D-N/D.
Impact Factor: 4.183
Dettagli Esporta in BibTeX Esporta in EndNote
Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G
* Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 alpha/beta pathways (190 visite)
Mol Carcinog (ISSN: 0899-1987linking), 2019 Mar 4; 58(7): 1181-1193.
Impact Factor: 3.851
Dettagli Esporta in BibTeX Esporta in EndNote
Bolzati C, Salvarese N, Carpanese D, Seraglia R, Melendez-alafort L, Rosato A, Capasso D, Saviano M, Del Gatto A, Comegna D, Zaccaro L
* [(99m)Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of alphavbeta3 Integrin: Synthesis, Structure-Activity and Pharmacokinetic Studies (354 visite)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print, 1520-4804electronic), 2018 Nov 8; 61(21): 9596-9610.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill B, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L
* Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer (595 visite) (PDF 130 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic, 1838-7640linking), 2018 Oct 6; 8(18): 5178-5199.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Comegna D, Zannetti A, Del Gatto A, De Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L
* Chemical Modification for Proteolytic Stabilization of the Selective alphavbeta3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells (897 visite) (PDF 195 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2017 Dec 14; 60(23): 9874-9884.
Impact Factor: 6.253
Dettagli Esporta in BibTeX Esporta in EndNote
Depalo N, Corricelli M, De Paola I, Valente G, Iacobazzi RM, Altamura E, Debellis D, Comegna D, Fanizza E, Denora N, Laquintana V, Mavelli F, Striccoli M, Saviano M, Agostiano A, Del Gatto A, Zaccaro L, Curri ML
* NIR Emitting Nanoprobes Based on Cyclic RGD Motif Conjugated PbS Quantum Dots for Integrin-Targeted Optical Bioimaging (383 visite) (PDF 176 visite)
Acs Appl Mater Inter (ISSN: 1944-8244), 2017 Dec 13; 9(49): 43113-43126.
Impact Factor: 8.097
Dettagli Esporta in BibTeX Esporta in EndNote
Hill BS, Pelagalli A, Passaro N, Zannetti A
* Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype (284 visite)
Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2017 Sep 22; 8(42): 73296-73311.
Impact Factor: 5.168
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A
* Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRbeta Aptamer (640 visite) (PDF 202 visite)
Theranostics (ISSN: 1838-7640, 1838-7640electronic), 2017 Aug 22; 7(14): 3595-3607.
Impact Factor: 8.537
Dettagli Esporta in BibTeX Esporta in EndNote
Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L
* Aptamer-mediated impairment of EGFR-integrin alphavbeta3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (431 visite) (PDF 215 visite)
Sci Rep (ISSN: 2045-2322, 2045-2322electronic, 2045-2322linking), 2017 Apr 20; 7: 46659-46659.
Impact Factor: 4.122
Dettagli Esporta in BibTeX Esporta in EndNote
Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (887 visite) (PDF 273 visite)
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 7.36
Dettagli Esporta in BibTeX Esporta in EndNote
Romano S, Staibano S, Greco A, Brunetti A, Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B, Romano M
* FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential (404 visite) (PDF 232 visite)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2013 Apr 4; 4(6): e578-e578.
Impact Factor: 5.333
Dettagli Esporta in BibTeX Esporta in EndNote
Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (410 visite)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (432 visite)
J Transl Med (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
Dettagli Esporta in BibTeX Esporta in EndNote
16 Records (15 escludendo Abstract e Conferenze).
Impact factor totale: 90.442 (85.109 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 76.42 (71.087 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Antonella Zannetti on in data Sunday 12 July 2020, 13:14:40
302 views visite. Last view on Ultima visita in data Wednesday 20 October 2021, 9:08:10
ibb.cnr.it